[Evidence on afatinib in patients progressing on a first-line treatment]

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are crucial in non-small cell lung cancer (NSCLC).
• Tyrosine-kinase inhibitors (TKIs) targeting EGFR mutations are standard first-line treatment for EGFR+ NSCLC.
• Disease progression despite TKI therapy necessitates alternative treatment strategies.

Purpose of the Study:

• To evaluate the efficacy and safety of afatinib in NSCLC patients progressing after first-generation TKI treatment.
• To assess afatinib's role as a second-line therapy, including in combination regimens.

Main Methods:

• Review of clinical trial data (e.g., LUX-LUNG-1) and real-world evidence from afatinib use in clinical practice.
• Analysis of response rates, progression-free survival, and toxicity profiles.

Main Results:

• Afatinib demonstrates significant response rates (7-15%) and progression-free survival in patients with acquired resistance to prior TKIs.
• Efficacy is observed irrespective of the T790M resistance mutation, attributed to continued pan-HER inhibition.
• Combination therapy with afatinib and cetuximab showed a high response rate.
• Afatinib toxicity in second-line settings is manageable and consistent with first-line use (e.g., mucocutaneous toxicity, diarrhea).

Conclusions:

• Afatinib is a viable treatment option for patients with EGFR-mutated NSCLC who have progressed on a first-generation TKI.
• Continued pan-HER inhibition by afatinib contributes to its efficacy in resistant disease.
• Afatinib's safety profile in second-line therapy is manageable, supporting its consideration in clinical practice.